Molecular and Clinical Profiles of Human Pegivirus Type 1 Infection in Individuals Living with HIV-1 in the Extreme South of Brazil
Human pegivirus type 1 (HPgV-1) infection has been associated with a beneficial effect on the prognosis of human immunodeficiency virus type 1 (HIV-1)-coinfected individuals. However, the mechanisms involved in this protection are not yet fully elucidated. To date, circulating HPgV-1 genotypes in HI...
Gespeichert in:
| Veröffentlicht in: | BioMed research international 2019-01, Vol.2019 (2019), p.1-11 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 11 |
|---|---|
| container_issue | 2019 |
| container_start_page | 1 |
| container_title | BioMed research international |
| container_volume | 2019 |
| creator | Groll, Andrea V. Silveira, Jussara M. Basso, Rossana P. Soares, Marcelo A. Martínez, Ana M. B. Chies, José Artur Luquez, Karen Y. Sánchez Gonçalves, Carla V. Nader, Maiba M. Germano, Fabiana N. Silva, Cláudio M. Finger-Jardim, Fabiana Mota, Luísa D. Da Hora, Vanusa P. Da |
| description | Human pegivirus type 1 (HPgV-1) infection has been associated with a beneficial effect on the prognosis of human immunodeficiency virus type 1 (HIV-1)-coinfected individuals. However, the mechanisms involved in this protection are not yet fully elucidated. To date, circulating HPgV-1 genotypes in HIV-1-infected individuals have not yet been identified in the extreme south of Brazil. The present study aimed to determine the genotypic circulation of HPgV-1 and the influence of HPgV-1 status and persistence time on the evolution of HIV-1 infection. A retrospective cohort of 110 coinfected individuals was analyzed. Samples were subjected to viral RNA extraction, cDNA synthesis, nested PCR, and genotyping. Genotypes 1 (2.8%), 2 (47.9% of subtype 2a and 42.3% of subtype 2b), and 3 (7%) were identified. In antiretroviral treatment-naïve subjects HPgV-1 subtype 2b was associated with lower HIV-1 viral load (VL) rates (p = 0.04) and higher CD4+ T-cell counts (p = 0.03) than was subtype 2a, and the positivity for HPgV-1 was associated with higher CD4+ T-cell counts (p = 0.02). However, there was no significant difference in HIV-1 VL between HPgV-1-positive and HPgV-1-negative subjects (p = 0.08). There was no significant association between the different groups in HPgV-1 persistence and median HIV-1 VL (p = 0.66) or CD4+ T-cell counts (p = 0.15). HPgV-1 subtype 2b is associated with better prognosis of HIV-1 infection. Although HPgV-1 infection is persistent, our data suggest that the time of infection does not influence HIV-1 VL or CD4+ T-cell counts in coinfected subjects. |
| doi_str_mv | 10.1155/2019/8048670 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6594344</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A612030601</galeid><sourcerecordid>A612030601</sourcerecordid><originalsourceid>FETCH-LOGICAL-c499t-ba357f2a120134794893a0a455344caed31caff79fc9c9c679dafa0a32e86c9c3</originalsourceid><addsrcrecordid>eNqNksFvFCEUxonR2GbtzbMh8WKiY2FgmOFiUjfV3WSNTaxeCWVgl4aFLcy01qv_uG-z61Y9CQcevB_f4wsPoeeUvKW0aU5rQuVpR3gnWvIIHdeM8kpQTh8fYsaO0Ekp1wRGRwWR4ik6YpQRSWl7jH5-SsGaMeiMdezxNPjojQ74Iifngy04OTwb1zriC7v0tz6PBV_ebyymeB6dNYNPEfsImx6y_ahDwQuI4hLf-WGFZ_NvFd0Cw8ri8-9DtmuLv6QRUqD8PusfPjxDTxzcsyf7dYK-fji_nM6qxeeP8-nZojJcyqG60qxpXa0pmGa8lbyTTBPNm4ZxbrTtGTXauVY6I2GKVvbaAcBq2wk4YBP0bqe7Ga_Wtjc2DlkHtcl-rfO9StqrvzPRr9Qy3SrRSA41QODVXiCnm9GWQa19MTYEHW0ai6rrpmsZl4IA-vIf9DqNOYI9oHjDBXyPeKCWOljlo0tQ12xF1ZkAn4wI8DpBb3aUyamUbN3hyZSobRuobRuofRsA_uJPmwf496cD8HoHrHzs9Z3_TzkLjHX6gaZ1KzrBfgFVJMK_</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2245462316</pqid></control><display><type>article</type><title>Molecular and Clinical Profiles of Human Pegivirus Type 1 Infection in Individuals Living with HIV-1 in the Extreme South of Brazil</title><source>MEDLINE</source><source>Wiley Online Library Open Access</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>PubMed Central Open Access</source><creator>Groll, Andrea V. ; Silveira, Jussara M. ; Basso, Rossana P. ; Soares, Marcelo A. ; Martínez, Ana M. B. ; Chies, José Artur ; Luquez, Karen Y. Sánchez ; Gonçalves, Carla V. ; Nader, Maiba M. ; Germano, Fabiana N. ; Silva, Cláudio M. ; Finger-Jardim, Fabiana ; Mota, Luísa D. Da ; Hora, Vanusa P. Da</creator><contributor>Lopalco, Lucia</contributor><creatorcontrib>Groll, Andrea V. ; Silveira, Jussara M. ; Basso, Rossana P. ; Soares, Marcelo A. ; Martínez, Ana M. B. ; Chies, José Artur ; Luquez, Karen Y. Sánchez ; Gonçalves, Carla V. ; Nader, Maiba M. ; Germano, Fabiana N. ; Silva, Cláudio M. ; Finger-Jardim, Fabiana ; Mota, Luísa D. Da ; Hora, Vanusa P. Da ; Lopalco, Lucia</creatorcontrib><description>Human pegivirus type 1 (HPgV-1) infection has been associated with a beneficial effect on the prognosis of human immunodeficiency virus type 1 (HIV-1)-coinfected individuals. However, the mechanisms involved in this protection are not yet fully elucidated. To date, circulating HPgV-1 genotypes in HIV-1-infected individuals have not yet been identified in the extreme south of Brazil. The present study aimed to determine the genotypic circulation of HPgV-1 and the influence of HPgV-1 status and persistence time on the evolution of HIV-1 infection. A retrospective cohort of 110 coinfected individuals was analyzed. Samples were subjected to viral RNA extraction, cDNA synthesis, nested PCR, and genotyping. Genotypes 1 (2.8%), 2 (47.9% of subtype 2a and 42.3% of subtype 2b), and 3 (7%) were identified. In antiretroviral treatment-naïve subjects HPgV-1 subtype 2b was associated with lower HIV-1 viral load (VL) rates (p = 0.04) and higher CD4+ T-cell counts (p = 0.03) than was subtype 2a, and the positivity for HPgV-1 was associated with higher CD4+ T-cell counts (p = 0.02). However, there was no significant difference in HIV-1 VL between HPgV-1-positive and HPgV-1-negative subjects (p = 0.08). There was no significant association between the different groups in HPgV-1 persistence and median HIV-1 VL (p = 0.66) or CD4+ T-cell counts (p = 0.15). HPgV-1 subtype 2b is associated with better prognosis of HIV-1 infection. Although HPgV-1 infection is persistent, our data suggest that the time of infection does not influence HIV-1 VL or CD4+ T-cell counts in coinfected subjects.</description><identifier>ISSN: 2314-6133</identifier><identifier>EISSN: 2314-6141</identifier><identifier>DOI: 10.1155/2019/8048670</identifier><identifier>PMID: 31309117</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Acquired immune deficiency syndrome ; Adult ; AIDS ; Antiretroviral agents ; Antiretroviral drugs ; B cells ; Brazil ; CD4 antigen ; CD4 Lymphocyte Count - methods ; Coinfection - virology ; Comorbidity ; Evolution ; Female ; GB virus C - genetics ; Genotype ; Genotype & phenotype ; Genotypes ; Genotyping ; Health aspects ; Hepatitis ; Highly active antiretroviral therapy ; HIV ; HIV (Viruses) ; HIV Infections - virology ; HIV patients ; HIV-1 - genetics ; Human immunodeficiency virus ; Humans ; Infection ; Infections ; Infectious diseases ; Laboratories ; Lymphocytes ; Lymphocytes T ; Male ; Patients ; Pilot Projects ; Prognosis ; Retrospective Studies ; Ribonucleic acid ; RNA ; RNA, Viral - genetics ; T cells ; Transcription ; Viral infections ; Viral Load - genetics ; Virology ; Viruses</subject><ispartof>BioMed research international, 2019-01, Vol.2019 (2019), p.1-11</ispartof><rights>Copyright © 2019 Luísa D. Da Mota et al.</rights><rights>COPYRIGHT 2019 John Wiley & Sons, Inc.</rights><rights>Copyright © 2019 Luísa D. Da Mota et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2019 Luísa D. Da Mota et al. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c499t-ba357f2a120134794893a0a455344caed31caff79fc9c9c679dafa0a32e86c9c3</citedby><cites>FETCH-LOGICAL-c499t-ba357f2a120134794893a0a455344caed31caff79fc9c9c679dafa0a32e86c9c3</cites><orcidid>0000-0003-3781-1221 ; 0000-0003-1652-2447 ; 0000-0001-7025-0660 ; 0000-0002-9013-2570</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594344/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594344/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31309117$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Lopalco, Lucia</contributor><creatorcontrib>Groll, Andrea V.</creatorcontrib><creatorcontrib>Silveira, Jussara M.</creatorcontrib><creatorcontrib>Basso, Rossana P.</creatorcontrib><creatorcontrib>Soares, Marcelo A.</creatorcontrib><creatorcontrib>Martínez, Ana M. B.</creatorcontrib><creatorcontrib>Chies, José Artur</creatorcontrib><creatorcontrib>Luquez, Karen Y. Sánchez</creatorcontrib><creatorcontrib>Gonçalves, Carla V.</creatorcontrib><creatorcontrib>Nader, Maiba M.</creatorcontrib><creatorcontrib>Germano, Fabiana N.</creatorcontrib><creatorcontrib>Silva, Cláudio M.</creatorcontrib><creatorcontrib>Finger-Jardim, Fabiana</creatorcontrib><creatorcontrib>Mota, Luísa D. Da</creatorcontrib><creatorcontrib>Hora, Vanusa P. Da</creatorcontrib><title>Molecular and Clinical Profiles of Human Pegivirus Type 1 Infection in Individuals Living with HIV-1 in the Extreme South of Brazil</title><title>BioMed research international</title><addtitle>Biomed Res Int</addtitle><description>Human pegivirus type 1 (HPgV-1) infection has been associated with a beneficial effect on the prognosis of human immunodeficiency virus type 1 (HIV-1)-coinfected individuals. However, the mechanisms involved in this protection are not yet fully elucidated. To date, circulating HPgV-1 genotypes in HIV-1-infected individuals have not yet been identified in the extreme south of Brazil. The present study aimed to determine the genotypic circulation of HPgV-1 and the influence of HPgV-1 status and persistence time on the evolution of HIV-1 infection. A retrospective cohort of 110 coinfected individuals was analyzed. Samples were subjected to viral RNA extraction, cDNA synthesis, nested PCR, and genotyping. Genotypes 1 (2.8%), 2 (47.9% of subtype 2a and 42.3% of subtype 2b), and 3 (7%) were identified. In antiretroviral treatment-naïve subjects HPgV-1 subtype 2b was associated with lower HIV-1 viral load (VL) rates (p = 0.04) and higher CD4+ T-cell counts (p = 0.03) than was subtype 2a, and the positivity for HPgV-1 was associated with higher CD4+ T-cell counts (p = 0.02). However, there was no significant difference in HIV-1 VL between HPgV-1-positive and HPgV-1-negative subjects (p = 0.08). There was no significant association between the different groups in HPgV-1 persistence and median HIV-1 VL (p = 0.66) or CD4+ T-cell counts (p = 0.15). HPgV-1 subtype 2b is associated with better prognosis of HIV-1 infection. Although HPgV-1 infection is persistent, our data suggest that the time of infection does not influence HIV-1 VL or CD4+ T-cell counts in coinfected subjects.</description><subject>Acquired immune deficiency syndrome</subject><subject>Adult</subject><subject>AIDS</subject><subject>Antiretroviral agents</subject><subject>Antiretroviral drugs</subject><subject>B cells</subject><subject>Brazil</subject><subject>CD4 antigen</subject><subject>CD4 Lymphocyte Count - methods</subject><subject>Coinfection - virology</subject><subject>Comorbidity</subject><subject>Evolution</subject><subject>Female</subject><subject>GB virus C - genetics</subject><subject>Genotype</subject><subject>Genotype & phenotype</subject><subject>Genotypes</subject><subject>Genotyping</subject><subject>Health aspects</subject><subject>Hepatitis</subject><subject>Highly active antiretroviral therapy</subject><subject>HIV</subject><subject>HIV (Viruses)</subject><subject>HIV Infections - virology</subject><subject>HIV patients</subject><subject>HIV-1 - genetics</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Infection</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Laboratories</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Male</subject><subject>Patients</subject><subject>Pilot Projects</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Ribonucleic acid</subject><subject>RNA</subject><subject>RNA, Viral - genetics</subject><subject>T cells</subject><subject>Transcription</subject><subject>Viral infections</subject><subject>Viral Load - genetics</subject><subject>Virology</subject><subject>Viruses</subject><issn>2314-6133</issn><issn>2314-6141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNksFvFCEUxonR2GbtzbMh8WKiY2FgmOFiUjfV3WSNTaxeCWVgl4aFLcy01qv_uG-z61Y9CQcevB_f4wsPoeeUvKW0aU5rQuVpR3gnWvIIHdeM8kpQTh8fYsaO0Ekp1wRGRwWR4ik6YpQRSWl7jH5-SsGaMeiMdezxNPjojQ74Iifngy04OTwb1zriC7v0tz6PBV_ebyymeB6dNYNPEfsImx6y_ahDwQuI4hLf-WGFZ_NvFd0Cw8ri8-9DtmuLv6QRUqD8PusfPjxDTxzcsyf7dYK-fji_nM6qxeeP8-nZojJcyqG60qxpXa0pmGa8lbyTTBPNm4ZxbrTtGTXauVY6I2GKVvbaAcBq2wk4YBP0bqe7Ga_Wtjc2DlkHtcl-rfO9StqrvzPRr9Qy3SrRSA41QODVXiCnm9GWQa19MTYEHW0ai6rrpmsZl4IA-vIf9DqNOYI9oHjDBXyPeKCWOljlo0tQ12xF1ZkAn4wI8DpBb3aUyamUbN3hyZSobRuobRuofRsA_uJPmwf496cD8HoHrHzs9Z3_TzkLjHX6gaZ1KzrBfgFVJMK_</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Groll, Andrea V.</creator><creator>Silveira, Jussara M.</creator><creator>Basso, Rossana P.</creator><creator>Soares, Marcelo A.</creator><creator>Martínez, Ana M. B.</creator><creator>Chies, José Artur</creator><creator>Luquez, Karen Y. Sánchez</creator><creator>Gonçalves, Carla V.</creator><creator>Nader, Maiba M.</creator><creator>Germano, Fabiana N.</creator><creator>Silva, Cláudio M.</creator><creator>Finger-Jardim, Fabiana</creator><creator>Mota, Luísa D. Da</creator><creator>Hora, Vanusa P. Da</creator><general>Hindawi Publishing Corporation</general><general>Hindawi</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3781-1221</orcidid><orcidid>https://orcid.org/0000-0003-1652-2447</orcidid><orcidid>https://orcid.org/0000-0001-7025-0660</orcidid><orcidid>https://orcid.org/0000-0002-9013-2570</orcidid></search><sort><creationdate>20190101</creationdate><title>Molecular and Clinical Profiles of Human Pegivirus Type 1 Infection in Individuals Living with HIV-1 in the Extreme South of Brazil</title><author>Groll, Andrea V. ; Silveira, Jussara M. ; Basso, Rossana P. ; Soares, Marcelo A. ; Martínez, Ana M. B. ; Chies, José Artur ; Luquez, Karen Y. Sánchez ; Gonçalves, Carla V. ; Nader, Maiba M. ; Germano, Fabiana N. ; Silva, Cláudio M. ; Finger-Jardim, Fabiana ; Mota, Luísa D. Da ; Hora, Vanusa P. Da</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c499t-ba357f2a120134794893a0a455344caed31caff79fc9c9c679dafa0a32e86c9c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>Adult</topic><topic>AIDS</topic><topic>Antiretroviral agents</topic><topic>Antiretroviral drugs</topic><topic>B cells</topic><topic>Brazil</topic><topic>CD4 antigen</topic><topic>CD4 Lymphocyte Count - methods</topic><topic>Coinfection - virology</topic><topic>Comorbidity</topic><topic>Evolution</topic><topic>Female</topic><topic>GB virus C - genetics</topic><topic>Genotype</topic><topic>Genotype & phenotype</topic><topic>Genotypes</topic><topic>Genotyping</topic><topic>Health aspects</topic><topic>Hepatitis</topic><topic>Highly active antiretroviral therapy</topic><topic>HIV</topic><topic>HIV (Viruses)</topic><topic>HIV Infections - virology</topic><topic>HIV patients</topic><topic>HIV-1 - genetics</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Infection</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Laboratories</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Male</topic><topic>Patients</topic><topic>Pilot Projects</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Ribonucleic acid</topic><topic>RNA</topic><topic>RNA, Viral - genetics</topic><topic>T cells</topic><topic>Transcription</topic><topic>Viral infections</topic><topic>Viral Load - genetics</topic><topic>Virology</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Groll, Andrea V.</creatorcontrib><creatorcontrib>Silveira, Jussara M.</creatorcontrib><creatorcontrib>Basso, Rossana P.</creatorcontrib><creatorcontrib>Soares, Marcelo A.</creatorcontrib><creatorcontrib>Martínez, Ana M. B.</creatorcontrib><creatorcontrib>Chies, José Artur</creatorcontrib><creatorcontrib>Luquez, Karen Y. Sánchez</creatorcontrib><creatorcontrib>Gonçalves, Carla V.</creatorcontrib><creatorcontrib>Nader, Maiba M.</creatorcontrib><creatorcontrib>Germano, Fabiana N.</creatorcontrib><creatorcontrib>Silva, Cláudio M.</creatorcontrib><creatorcontrib>Finger-Jardim, Fabiana</creatorcontrib><creatorcontrib>Mota, Luísa D. Da</creatorcontrib><creatorcontrib>Hora, Vanusa P. Da</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Middle East & Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BioMed research international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Groll, Andrea V.</au><au>Silveira, Jussara M.</au><au>Basso, Rossana P.</au><au>Soares, Marcelo A.</au><au>Martínez, Ana M. B.</au><au>Chies, José Artur</au><au>Luquez, Karen Y. Sánchez</au><au>Gonçalves, Carla V.</au><au>Nader, Maiba M.</au><au>Germano, Fabiana N.</au><au>Silva, Cláudio M.</au><au>Finger-Jardim, Fabiana</au><au>Mota, Luísa D. Da</au><au>Hora, Vanusa P. Da</au><au>Lopalco, Lucia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Molecular and Clinical Profiles of Human Pegivirus Type 1 Infection in Individuals Living with HIV-1 in the Extreme South of Brazil</atitle><jtitle>BioMed research international</jtitle><addtitle>Biomed Res Int</addtitle><date>2019-01-01</date><risdate>2019</risdate><volume>2019</volume><issue>2019</issue><spage>1</spage><epage>11</epage><pages>1-11</pages><issn>2314-6133</issn><eissn>2314-6141</eissn><abstract>Human pegivirus type 1 (HPgV-1) infection has been associated with a beneficial effect on the prognosis of human immunodeficiency virus type 1 (HIV-1)-coinfected individuals. However, the mechanisms involved in this protection are not yet fully elucidated. To date, circulating HPgV-1 genotypes in HIV-1-infected individuals have not yet been identified in the extreme south of Brazil. The present study aimed to determine the genotypic circulation of HPgV-1 and the influence of HPgV-1 status and persistence time on the evolution of HIV-1 infection. A retrospective cohort of 110 coinfected individuals was analyzed. Samples were subjected to viral RNA extraction, cDNA synthesis, nested PCR, and genotyping. Genotypes 1 (2.8%), 2 (47.9% of subtype 2a and 42.3% of subtype 2b), and 3 (7%) were identified. In antiretroviral treatment-naïve subjects HPgV-1 subtype 2b was associated with lower HIV-1 viral load (VL) rates (p = 0.04) and higher CD4+ T-cell counts (p = 0.03) than was subtype 2a, and the positivity for HPgV-1 was associated with higher CD4+ T-cell counts (p = 0.02). However, there was no significant difference in HIV-1 VL between HPgV-1-positive and HPgV-1-negative subjects (p = 0.08). There was no significant association between the different groups in HPgV-1 persistence and median HIV-1 VL (p = 0.66) or CD4+ T-cell counts (p = 0.15). HPgV-1 subtype 2b is associated with better prognosis of HIV-1 infection. Although HPgV-1 infection is persistent, our data suggest that the time of infection does not influence HIV-1 VL or CD4+ T-cell counts in coinfected subjects.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>31309117</pmid><doi>10.1155/2019/8048670</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-3781-1221</orcidid><orcidid>https://orcid.org/0000-0003-1652-2447</orcidid><orcidid>https://orcid.org/0000-0001-7025-0660</orcidid><orcidid>https://orcid.org/0000-0002-9013-2570</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2314-6133 |
| ispartof | BioMed research international, 2019-01, Vol.2019 (2019), p.1-11 |
| issn | 2314-6133 2314-6141 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6594344 |
| source | MEDLINE; Wiley Online Library Open Access; PubMed Central; Alma/SFX Local Collection; PubMed Central Open Access |
| subjects | Acquired immune deficiency syndrome Adult AIDS Antiretroviral agents Antiretroviral drugs B cells Brazil CD4 antigen CD4 Lymphocyte Count - methods Coinfection - virology Comorbidity Evolution Female GB virus C - genetics Genotype Genotype & phenotype Genotypes Genotyping Health aspects Hepatitis Highly active antiretroviral therapy HIV HIV (Viruses) HIV Infections - virology HIV patients HIV-1 - genetics Human immunodeficiency virus Humans Infection Infections Infectious diseases Laboratories Lymphocytes Lymphocytes T Male Patients Pilot Projects Prognosis Retrospective Studies Ribonucleic acid RNA RNA, Viral - genetics T cells Transcription Viral infections Viral Load - genetics Virology Viruses |
| title | Molecular and Clinical Profiles of Human Pegivirus Type 1 Infection in Individuals Living with HIV-1 in the Extreme South of Brazil |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T07%3A53%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Molecular%20and%20Clinical%20Profiles%20of%20Human%20Pegivirus%20Type%201%20Infection%20in%20Individuals%20Living%20with%20HIV-1%20in%20the%20Extreme%20South%20of%20Brazil&rft.jtitle=BioMed%20research%20international&rft.au=Groll,%20Andrea%20V.&rft.date=2019-01-01&rft.volume=2019&rft.issue=2019&rft.spage=1&rft.epage=11&rft.pages=1-11&rft.issn=2314-6133&rft.eissn=2314-6141&rft_id=info:doi/10.1155/2019/8048670&rft_dat=%3Cgale_pubme%3EA612030601%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2245462316&rft_id=info:pmid/31309117&rft_galeid=A612030601&rfr_iscdi=true |